When advanced breast cancer is in remission, which treatment works
Time of Update: 2022-10-20
Results of PET-CT imaging before the first round of treatmentIn January 2019, after a few months of overall treatment, tests revealed that all of the patient's tumors had disappeared, doctors speculated that chemotherapy and targeted drugs worked, and it was unclear what role the cannabinoids and psilocybin played.
Immunotherapy enables patients with gastroesophageal cancer to achieve a high rate of complete remission
Time of Update: 2022-10-13
Commenting on NEONIPIGA is a landmark study that shows that patients with MSI-H esophageal gastric adenocarcinoma achieve high pathological complete remission rates after receiving neoadjuvant therapy with ipimumab and navurizumab.
Bristol-Myers Squibb relatlimab for the treatment of melanoma
Time of Update: 2022-10-03
Immune checkpoint inhibitors are a class of cancer immunotherapies that have been approved for 8 drugs, 7 of which have a mechanism similar to the PD-1 inhibitors sintilimab (Xindilizumab) of Eli Lilly and Cinda Biologics, which have been marketed in China under the brand name Tyvyt (Dabosu).
Research express | "old therapies" have a significant impact on pediatric brain tumors
Time of Update: 2022-09-14
"Disulfiram [DSF], a drug that has been used to treat chronic alcoholism for nearly 70 years, is promising to be 'repurposed' as an anti-cancer agent, especially when it is complexed with metal ions such as copper [Cu++]," said Study senior author Betty Tyler, an associate professor of neurosurgery at the Johns Hopkins University School of Medicine.
One case of esophageal mushroom-type sarcoma-like carcinoma
Time of Update: 2022-09-14
Barium upper gastrointestinal meal: a large fusiform filling defect is seen in the lumen of the subthophagus thorax, about 9 cm long, the boundary with the adjacent normal esophagus is clearer, the tube wall is still soft, no obvious signs of obstruction are seen through the contrast medium, and the mucosal interruption is destroyed (Figure 1).
Minimally invasive in minimally invasive
Time of Update: 2022-09-07
Figure 1 Surgical incision of conventional laparoscopic radical sigmoidectomyIn the operation performed by Deputy Chief Physician Yang Shibin, only 3 Trocar holes were punched in the abdomen of the patient for the operation.
A&R: A risk score for detecting subclinical rheumatoid arthritis-associated interstitial lung disease
Time of Update: 2022-08-12
. Conclusions: This study identifies and validates a risk score for RA-ILD with or without MUC5B rs35705950 that identifies patients at high risk for subclinical RA-ILD requiring screening with chest HRCT scans .
For adjuvant treatment of NSCLC
Time of Update: 2022-05-24
On April 11, the CDE official website showed that BeiGene's tislelizumab + osperizumab combination therapy was approved for clinical use in adjuvant and neoadjuvant treatment of non-small cell lung cancer .
First-line treatment of non-small cell lung cancer mRNA vaccine/PD-1 antibody combination is about to enter the clinic
Time of Update: 2022-04-30
On March 9, BioNTech announced that it has expanded its strategic R&D cooperation with Regeneron, and will jointly promote the clinical trial of BioNTech's candidate cancer vaccine BNT116 in combination with the PD-1 inhibitor Libtayo (cemiplimab) for the treatment of advanced stage Non-small cell lung cancer (NSCLC) patients .
Front Oncol: The prognostic role of the number of resected lymph nodes in stage II small bowel adenocarcinoma (SBA) based on the SEER database
Time of Update: 2022-04-23
According to the National Comprehensive Cancer Network (NCCN) guidelines, insufficient examination of lymph nodes (LNs) (<5 duodenum and <8 primary sites of jejunum/ileum) is one of the high-risk factors for stage II patients, and adjuvant chemotherapy is recommended .
J Immunother Cancer: The efficacy of PD-1 inhibitor combined with chemotherapy in neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma
Time of Update: 2022-01-23
Therefore, a team from the First Affiliated Hospital of Sun Yat-Sen University conducted a related study to evaluate the efficacy of PD-1 inhibitor combined with chemotherapy in neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma .
New drug development focuses on infectious diseases
Time of Update: 2022-01-01
Nuzero is a new type of antibiotic, available in oral and intravenous infusion formulations, approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) .
Good news for diabetics
Time of Update: 2021-11-15
Recently, Novo Nordisk’s self-developed innovative drug in the field of diabetes-insulin deglulam and liraglutide injection (Novozymes) was officially approved by the National Medical Products Administration (NMPA), which means that the drug is The world's first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection was approved in China, and a new era of China's type 2 diabetes (T2DM) treatment has officially opened!
Front Oncol: Palbociclib combined with letrozole in the first-line treatment of HR+ /HER2- predictors of primary drug resistance in metastatic breast cancer (MBC
Time of Update: 2021-11-12
Recently, scholars from South Korea have carried out related studies to assess which clinical parameters can predict the primary drug resistance of palbociclib combined with letrozole as the first-line treatment of HR+ /HER2-MBC patients .
Pancreatic cancer is difficult to treat, the virus will help
Time of Update: 2021-10-01
New research shows that the oncolytic virus H-1PV shows considerable safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) .
"Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Immune Cell Activity in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.